Method AI Raises $20M in Series A Financing to Enhance Physician Visualization During Surgical Oncology Procedures

方法AI在A轮融资中筹集2000万美元，以增强外科肿瘤手术期间的医生可视化能力。

New funding to support building image-guided surgical navigation platform

新资金支持构建影像引导的手术导航平台

BOSTON, August 21, 2025-- Method AI, a medical technology company focused on improving oncology outcomes through image-guided surgical navigation, announced today it has raised $20 million in Series A funding. Method AI emerged from Cleveland Clinic in 2021 to resolve surgical visualization challenges experienced by their leading robotic surgeons.

波士顿，2025年8月21日——Method AI，一家专注于通过影像引导手术导航改善肿瘤治疗效果的医疗技术公司，今天宣布已完成2000万美元的A轮融资。Method AI于2021年从克利夫兰诊所分离出来，旨在解决其领先的机器人外科医生所面临的手术可视化挑战。

The financing round, led by a private family office with participation from Cleveland Clinic and JobsOhio Growth Capital Fund, will support continued development of the company’s novel surgical ultrasound platform..

本轮融资由一家私人家族办公室领投，克利夫兰诊所和 JobsOhio 增长资本基金参与，将支持公司新型外科超声平台的持续开发。

Method AI’s technology visualizes anatomy that lies deep below the visible surface of an organ – anatomy that is beyond the view of today’s surgical camera systems. The platform will create a first-of-its-kind 3D subsurface map for physicians while providing them with real-time guidance against an AI-generated surgical plan.

Method AI的技术能够可视化器官表面深处的解剖结构——这些解剖结构超出了当今手术摄像系统的视野范围。该平台将为医生创建首个此类3D次表面地图，同时根据AI生成的手术计划提供实时指导。

The company aims to significantly improve the cancer-free survival rate for patients, with the potential to reduce over $1 billion in annual cost from the broader healthcare system..

这家公司有望大幅提高患者的无癌生存率，为更广泛的医疗保健系统每年节省超过 10 亿美元的开支。

“In complex oncology procedures, surgeons often have to remove tumors that are partially or completely embedded within the organ, making it extremely difficult to gauge the margins of the tumor during a live surgery,” said Doug Teany, Co-Founder and CEO of Method AI. “This incomplete view of the tumor and other critical anatomy leads to cancer left behind, unforeseen complications and loss of organ function.

“在复杂的肿瘤学手术中，外科医生常常需要切除部分或完全嵌入器官内的肿瘤，这使得在实时手术中很难判断肿瘤的边界，”Method AI的联合创始人兼首席执行官Doug Teany说道。“这种对肿瘤和其他关键解剖结构的不完整视野，会导致癌细胞残留、意外并发症以及器官功能的丧失。”

With the support of our investment partners, our technology can make the difference between completely removing a tumor or leaving part of it behind, which significantly impacts long-term patient outcomes.”.

在我们的投资合作伙伴的支持下，我们的技术可以决定是完全切除肿瘤还是留下部分肿瘤，这对患者的长期治疗效果有着显著的影响。

Despite advancements in robotic and minimally invasive procedures, up to 40% of surgeries fail to fully remove the cancer. Method AI is developing a surgical navigation platform that allows for continuous 3D ultrasound imaging throughout a procedure. Its real-time algorithms build a map of critical subsurface features and will leverage machine learning to generate plans that guide physicians to the best possible surgical outcome..

尽管机器人技术和微创手术取得了进步，但仍有高达40%的手术未能完全切除癌组织。Method AI正在开发一款手术导航平台，可以在手术过程中实现连续的3D超声成像。其即时算法构建关键地下特征的地图，并将利用机器学习生成帮助医生达到最佳手术效果的方案。

To learn more about Method AI, please visit: www.methodsurgical.ai

要了解更多关于 Method AI 的信息，请访问：www.methodsurgical.ai

About Method AI

关于Method AI

Method AI is a medical technology company pioneering image-guided surgical navigation to improve patient outcomes. Its platform leverages continuous, 3D ultrasound and AI-generated surgical plans to guide robotic-assisted procedures. Based outside Boston, Mass. and led by a team with deep medical device expertise, Method AI is reimagining the field of view for surgeons during complex, life-saving procedures.

Method AI是一家医疗技术公司，率先采用图像引导的手术导航来改善患者的治疗效果。其平台利用连续的3D超声和人工智能生成的手术计划来引导机器人辅助手术。公司位于马萨诸塞州波士顿郊外，由一支拥有深厚医疗器械专业知识的团队领导，Method AI正在重新构想外科医生在复杂、挽救生命的手术中的视野。

To learn more about Method AI, visit www.methodsurgical.ai..

要了解有关 Method AI 的更多信息，请访问 www.methodsurgical.ai。

The Method AI platform is currently under development. It is not yet cleared for commercial distribution in any country.

Method AI 平台目前正在开发中，尚未在任何国家获得商业分发的许可。

Contact:

联系人：

Matter for Method AI

方法人工智能的材料

MethodSurgical@matternow.com

方法外科@物质现在.com